Entrada Therapeutics (TRDA) Interest & Investment Income (2020 - 2026)

Entrada Therapeutics' Interest & Investment Income history runs 7 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• In Q1 2026, Interest & Investment Income fell 40.91% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $13.3 million (down 32.72% YoY), while the FY2025 annual figure was $15.1 million, down 22.6% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $2.6 million, down from $3.1 million in the prior quarter.
• The five-year high for Interest & Investment Income was $5.8 million in Q3 2024, with the low at -$3.7 million in Q4 2022.
• The 5-year median for Interest & Investment Income is $3.9 million (2025), against an average of $3.0 million.
• Peak annual rise in Interest & Investment Income reached 4377.78% in 2022, while the deepest fall reached 8597.73% in 2022.
• Entrada Therapeutics' Interest & Investment Income stood at -$3.7 million in 2022, then jumped by 214.79% to $4.3 million in 2023, then gained by 19.48% to $5.1 million in 2024, then sank by 38.85% to $3.1 million in 2025, then declined by 16.33% to $2.6 million in 2026.
• Business Quant data shows TRDA's Interest & Investment Income at $2.6 million in Q1 2026, $3.1 million in Q4 2025, and $3.6 million in Q3 2025.